|
A drug that showed promise in slowing kidney disease in people with Type 1 diabetes has no clinical benefit for patients, according to results from a three-year clinical trial published in the New England Journal of Medicine. “This is not the result that we wanted,†said Peter Senior, a professor of medicine at the University of Alberta who was involved in the international study, “but it does give a very clear answer to an important scientific question.â€
|